On November 5, Taysha Gene Therapies is trading 5.6% lower at $4.12; no clear company-specific catalyst has emerged, while a broad risk-off selloff is the likeliest explanation, though reports do not directly link it. - The company announced today that it will report third-quarter results and provide a corporate update on November 12; it did not report new results. - Biotech ETF XBI was down 5.19%, while major indexes were sharply lower.